Cargando…
Nebulized formoterol: a review of clinical efficacy and safety in COPD
A nebulized formulation of formoterol, Perforomist(®), 20 μg/2 ml, has been available since 2007 for the maintenance treatment of chronic obstructive pulmonary disease (COPD). We review the safety and efficacy data obtained during its development. In a dose-finding study, formoterol inhalation solut...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921690/ https://www.ncbi.nlm.nih.gov/pubmed/20714376 |